@trilok why don't you start an IPO thread and carry on this discussion. Let's not hijack this thread.
Coming back to your questions:
1) They are ranked 32 by IPM market share and have only 0.7% market share. So huge opportunity to grow from here. While sales have grown at 14% in last year, EBITDA and PAT cagr are 26% and 33%.
2) Eris derives 98% of sales from branded formulations and is backed by very strong brands specially in Cardio which are growing at 2X market size. They have acquired 2 companies in 2016 and have huge cash chest ready for future inorganic growth.
As discussed before the fundamentals are excellent, but IPO is very expensive. An investor needs to decide on their investment horizon and growth expectations and decide accordingly. Thanks.